US Stock MarketDetailed Quotes
IKT Inhibikase Therapeutics
- 1.7100
- -0.1900-10.00%
Close Apr 26 16:00 ET
11.08MMarket Cap-478P/E (TTM)
1.8200High1.6700Low98.98KVolume1.6700Open1.9000Pre Close170.48KTurnover1.78%Turnover RatioLossP/E (Static)6.48MShares4.351252wk High1.01P/B9.53MFloat Cap0.790052wk Low--Dividend TTM5.57MShs Float70.8000Historical High--Div YieldTTM7.90%Amplitude0.7900Historical Low1.7220Avg Price1Lot Size
Inhibikase Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -4.23%-18.09M | 3.20%-3.44M | 25.43%-4.11M | -4.81%-4.57M | -51.80%-5.97M | -21.36%-17.35M | 13.17%-3.56M | -172.44%-5.5M | -2.57%-4.36M | 0.00%-3.93M |
| Net income from continuing operations | -5.40%-19.03M | 2.36%-4.18M | -2.24%-4.6M | -24.53%-5.78M | 3.51%-4.48M | -22.10%-18.05M | 15.13%-4.28M | -0.52%-4.49M | -76.01%-4.64M | -75.98%-4.64M |
| Depreciation and amortization | 2,538.67%177.4K | 30.27%6.57K | 291.61%6.58K | --159.2K | --5.04K | --6.72K | --5.04K | --1.68K | --0 | --0 |
| Other non cash items | -52.93%31.54K | 168.48%14.26K | ---- | ---- | ---- | 104.01%67K | ---20.82K | --20.82K | --0 | 104.01%67K |
| Change In working capital | 37.14%234.76K | -7.15%592.44K | 129.66%336.46K | 513.42%928.53K | -414.36%-1.62M | 109.70%171.18K | -1.85%638.09K | -159.19%-1.13M | 106.97%151.37K | 123.91%516.18K |
| -Change in receivables | -43.24%39.88K | --0 | 1,191.93%79.6K | -136.41%-15.08K | -139.63%-24.64K | 163.79%70.26K | -124.26%-26.04K | -101.98%-7.29K | 116.32%41.42K | 118.68%62.17K |
| -Change in prepaid assets | 156.32%842.42K | 78.32%280.45K | -14.42%250.05K | 541,297.53%876.74K | -368.16%-564.82K | 142.11%328.66K | 119.56%157.28K | -70.40%292.19K | 99.99%-162 | -146.00%-120.65K |
| -Change in payables and accrued expense | -151.20%-642.89K | -37.50%313.95K | 100.54%7.7K | -21.58%67.77K | -279.64%-1.03M | -117.63%-255.93K | -62.70%502.34K | -301.88%-1.42M | -79.23%86.42K | 156.67%574.66K |
| -Change in other current assets | 179.64%106.42K | ---- | ---- | ---- | --25.38K | --38.06K | ---- | ---- | ---- | --0 |
| -Change in other current liabilities | -1,026.56%-111.07K | -202.51%-29.82K | ---27.89K | ---27.07K | ---26.28K | ---9.86K | ---9.86K | --0 | --0 | --0 |
| -Change in other working capital | ---- | ---- | 2,700,300.00%27K | ---- | ---- | ---- | ---- | 100.00%-1 | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -4.23%-18.09M | 3.20%-3.44M | 25.43%-4.11M | -4.81%-4.57M | -51.80%-5.97M | -21.36%-17.35M | 13.17%-3.56M | -172.44%-5.5M | -2.57%-4.36M | 0.00%-3.93M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 172.83%11.66M | -142.63%-2.12M | 181.53%17.06M | 6,017.70%2.55M | -5.84M | -16.01M | 4.96M | -20.93M | -43.09K | 0 |
| Net PPE purchase and sale | 94.15%-14.24K | --0 | --0 | ---- | ---- | ---243.26K | --0 | ---200.17K | ---- | ---- |
| Net investment purchase and sale | 174.04%11.67M | -142.63%-2.12M | 182.32%17.06M | --2.56M | ---5.84M | ---15.76M | --4.96M | ---20.73M | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 172.83%11.66M | -142.63%-2.12M | 181.53%17.06M | 6,017.70%2.55M | ---5.84M | ---16.01M | --4.96M | ---20.93M | ---43.09K | --0 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 4,204.63%8.41M | -138.1K | 70 | -35.99K | 4,289.61%8.58M | -100.50%-204.77K | 0 | 0 | 0 | 50.02%-204.77K |
| Net issuance payments of debt | --0 | --0 | --0 | --0 | --0 | -485.20%-248.91K | --0 | --0 | --0 | 39.24%-248.91K |
| Net common stock issuance | --8.54M | --452 | --70 | ---35.99K | --8.58M | --0 | --0 | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | --0 | --0 | --0 | --0 | --0 | -43.77%44.14K | --0 | --0 | --0 | --44.14K |
| Net other financing activities | ---138.56K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 4,204.63%8.41M | ---138.1K | --70 | ---35.99K | 4,289.61%8.58M | -100.50%-204.77K | --0 | --0 | --0 | 50.02%-204.77K |
| Net cash flow | ||||||||||
| Beginning cash position | -82.36%7.19M | 157.03%14.86M | -94.09%1.91M | -89.19%3.96M | -82.36%7.19M | 192.04%40.75M | -87.11%5.78M | -31.22%32.21M | 280.98%36.61M | 192.04%40.75M |
| Current changes in cash | 105.89%1.98M | -504.95%-5.7M | 149.02%12.96M | 53.36%-2.05M | 21.91%-3.23M | -225.25%-33.56M | 134.34%1.41M | -1,227.75%-26.43M | -111.82%-4.4M | 4.72%-4.14M |
| End cash Position | 27.50%9.17M | 27.50%9.17M | 157.03%14.86M | -94.09%1.91M | -89.19%3.96M | -82.36%7.19M | -82.36%7.19M | -87.11%5.78M | -31.22%32.21M | 280.98%36.61M |
| Free cash flow | -2.87%-18.1M | 3.20%-3.44M | 28.04%-4.11M | -4.11%-4.58M | -51.80%-5.97M | -23.06%-17.59M | 13.17%-3.56M | -182.35%-5.7M | -3.59%-4.4M | 0.00%-3.93M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg